ArticleFrontiers in psychiatry2025
Altered plasma fatty acids composition in autism spectrum disorder: a case-control study.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Due to the variability in clinical manifestations and the frequent diagnostic delays associated with autism spectrum disorder (ASD), interest in identifying fatty acids as potential biomarkers is increasing. Nonetheless, owing to inconclusive evidence, further investigation is needed. Objective: To explore the relationship between fatty acids and ASD risk and identify distinct fatty acid metabolites in children with ASD. Methods: Plasma fatty acid levels were tested in totally 131 participants (ages 2-6 and male-to-female ratio 2.5:1) with and without ASD using gas chromatography coupled to flame ionization detector and mass spectrometer (GC-FID/MS) technology. Between-group differences in each fatty acid and the omega-3 polyunsaturated fatty acid/arachidonic acid (AA) ratio were explored. We adjusted for covariates via multivariable models. The discriminatory sensitivity of meaningful fatty acids between ASD and control groups was assessed via receiver operating characteristic curve (ROC) analysis. Results: Two of 22 fatty acids significantly differed between children with ASD and typically developing children. Specifically, C20:4ω6 (AA) (457.4 ± 195.3 μmol/L Conclusions: Fatty acid disturbance was observed among children with ASD, particularly in terms of AA, C24:0 and the ALA/AA ratio. These findings provide valuable insights into the underlying mechanisms of ASD and suggest that modulating fatty acid levels could serve as an intervention strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.